EGFR and non-small cell lung carcinoma: Except for the 3rd EGFR-TKIs, which is approved for the treatment of NSCLC patients with positive T790M mutation after developing AR to the first-line EGFR-TKIs [14], the efficacy of other personalized therapeutic strategies is largely compromised by small samples and absence of comparison with chemotherapy.